期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 360, 期 26, 页码 2749-2757出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMcp0900449
关键词
-
资金
- GlaxoSmithKline
- AstraZeneca and serving on advisory boards for the Alpha-1 Foundation
- Kamada
- Biotherapeutics
- CSL Behring
A 60-year-old white man presents for evaluation of progressive dyspnea. He is a former smoker with a 20-pack-year smoking history and a 10-year history of diagnosed chronic obstructive pulmonary disease (COPD). There is no family history of COPD. Severe airflow obstruction is seen on spirometry, with a forced expiratory volume in 1 second (FEV1) that is 40% of the predicted value. Should the patient be evaluated for alpha(1)-antitrypsin (AAT) deficiency? If AAT deficiency is documented, how should his case be managed?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据